Clinical commissioning policy: Dabrafenib for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed (all ages)

Document first published:
Page updated:
Topic:
Publication type:

Dabrafenib is recommended to be available off-label as a routine commissioning treatment option for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed within the criteria set out in this document. This policy is for all ages in line with the findings from the evidence review.

Document

Clinical commissioning policy: Dabrafenib for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed (all ages)

Clinical commissioning policy: Dabrafenib for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed (all ages)

  • PDF
  • 237 KB

Summary

Published 16 July 2026.